Trials / Unknown
UnknownNCT00057395
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
A Phase I/II Study of Aroplatin™ in Patients With Advanced Solid Malignancies
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Aronex Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
Detailed description
Primary Objective: * Determine response rate (RR; complete and partial response \[CR, PR\]) and duration after therapy with Aroplatin™ in patients with advanced solid malignancies. Secondary Objective: * Determine the safety and tolerability of Aroplatin
Conditions
- Esophageal Neoplasms
- Hepatocellular Carcinoma
- Colorectal Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aroplatin (Liposomal NDDP, L-NDDP) |
Timeline
- First posted
- 2003-04-02
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00057395. Inclusion in this directory is not an endorsement.